A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.

Front Endocrinol (Lausanne) · 2025 · PMC12277171 · PMID 40692593

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

Another meta-analysis evaluating three CVOTs with SGLT-2 inhibitors (N = 34,322) showed a reduction in MACE in men (RR 0.90; 95% CI, 0.83–0.97; p = 0.006), whereas in women, the risk reduction did not reach statistical significance (RR 0.88; 95% CI, 0.77–1.00; p = 0.06) ( 100 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.